Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
CureVac NV (CVAC)
116.15 ? 0.48 (0.41%)
Volume: 326,840 @05/26/21 11:50:12 AM EDT
Bid Ask Day's Range
115.96 116.15 112.3 - 117.41
CVAC Detailed Quote
Pfizer,s Ceo says that it will take a third dose of his mRNA vaccine at nine months, maybe Curevac's will work the same, let's go Curecaaaaaaaaav for 180 $$$$$$$$$
120$/share
Curevac is close to getting approval for its first major drug! And much more important is the technology of this vaccine for the world, both for the West and for the rest!
A new blow to the supply of vaccines, specifically to Inovio, which uses technology other than mRNA.
Increase the pressure for effective vaccines.
https://www.reuters.com/business/healthcare-pharmaceuticals/us-government-stops-funding-inovio-covid-19-vaccine-study-2021-04-23/
We will need a third booster shot for the next vaccination campaign. Curevac uses the same mRNA technology in the vaccine as Pfizer.
https://www.cnbc.com/2021/04/21/scientist-who-helped-develop-pfizer-biontech-covid-vaccine-agrees-third-shot-is-needed-as-immunity-wanes.html
Israel begins to source mRNA vaccines until 2022.
https://www.reuters.com/world/middle-east/israel-signs-deal-buy-millions-covid-19-vaccine-doses-pfizer-netanyahu-says-2021-04-19/
114$/share
"Swiss drugmaker Novartis has agreed to help make CureVac's vaccine at a plant in Austria. The German company is aiming to release pivotal data from its clinical trial on the efficacy of its candidate early in the second quarter"
https://finance.yahoo.com/news/curevac-starts-review-process-switzerland-114512049.html
"Expanded manufacturing network with European partners expected to manufacture up to 300 million doses of CVnCoV by end of 2021 and up to one billion doses in 2022
Partnerships with Bayer, GSK and the UK government (partnership under final discussions) to rapidly advance first-generation vaccines and expand into second-generation vaccines in our COVID-19 program"
https://www.curevac.com/en/2021/04/15/curevac-announces-financial-results-and-business-updates-for-the-fourth-quarter-and-full-year-of-2020/
CureVac NV (CVAC)
109.99 ? 5.94 (5.71%)
Volume: 1,585,092 @04/16/21 7:59:33 PM EDT
Bid Ask Day's Range
109.93 110.98 104.4 - 109.29
CVAC Detailed Quote
Demand for effective vaccines increases in Europe and in the world, Curevac is the next protagonist.
Doubts about Astrazeneca continue.
https://www.bloomberg.com/news/articles/2021-04-12/eu-urged-to-agree-to-bloc-wide-age-curbs-on-astrazeneca-vaccine
Trouble begins for johnson and johnson.
https://floridapolitics.com/archives/419611-u-s-recommends-pause-for-jj-vaccine-over-clot-reports/
https://www.cnbc.com/2021/04/08/covid-vaccine-maker-curevac-hopes-shot-will-get-eu-approval-in-june.html
" The company is already producing its vaccine, despite the fact it has not yet been authorized, in anticipation of the shot’s approval"
"CureVac reaffirms an expected output capacity of its broad European manufacturing network of up to 300 million doses in 2021"
https://www.curevac.com/en/2021/03/30/celonic-and-curevac-announce-agreement-to-manufacture-over-100-million-doses-of-curevacs-covid-19-vaccine-candidate-cvncov/
Great demand for vaccines in Europe and in the world, Curevac increases production agreement with large pharmaceutical companies. This is all good news.
CureVac NV (CVAC)
104.9 ? -1.36 (-1.28%)
Volume: 968,317 @02/19/21 7:50:29 PM EST
Bid Ask Day's Range
104.0 108.7 103.6 - 110.12
CVAC Detailed Quote
CureVac NV (CVAC)
104.9 ? -1.36 (-1.28%)
Volume: 968,317 @02/19/21 7:50:29 PM EST
Bid Ask Day's Range
104.0 108.7 103.6 - 110.12
CVAC Detailed Quote
WOW CVAC OUTSTANDING
Can’t believe I bought this at 67 and then got nervous and sold at 68. Idiot.
CureVac NV (CVAC)
113.25 ? 7.1 (6.69%)
Volume: 365,353 @12/07/20 12:58:05 PM EST
Bid Ask Day's Range
113.18 113.25 108.46 - 113.84
CVAC Detailed Quote
CureVac's bigger story
However, CureVac won't need Tesla's Midas touch to succeed with its bigger story. It's one of only three companies with COVID-19 vaccine candidates currently in phase 2 testing. The other two are Chinese drugmakers. This puts CureVac's vaccine candidate CVnCoV behind only five others in late-stage testing that could be commercialized in major Western markets.
CureVac plans to advance CVnCOV into a pivotal phase 2b/3 clinical study by the end of 2020. If all goes well, the biotech seems likely to become one of the biggest COVID vaccine winners.
The company recently lined up an agreement with the European Commission to supply up to 225 million doses of CVnCOV (assuming it secures regulatory approval). The deal includes an option for the EC to buy an additional 180 million doses. Although no financial details were revealed, CureVac likely stands to make several billion dollars in 2021 if CVnCOV is proven to be safe and effective in late-stage testing.
CVnCOV can be stored at standard refrigerator temperatures for up to three months and for up to 24 hours at room temperature. This could give it an advantage over vaccines such as Pfizer's and BioNTech's BNT162b2, which must be stored at ultracold temperatures.
One to watch
Success for CVnCOV could bode well for the rest of CureVac's mRNA pipeline. The company is evaluating a rabies vaccine and two cancer immunotherapy candidates in phase 1 clinical studies. CureVac also has several other preclinical programs.
It's still too early to know for sure if CVnCOV will achieve similar efficacy to the results announced by Pfizer and Moderna. However, CureVac is without question a biotech stock for investors to keep on their radars.
Keith Speights owns shares of Pfizer. The Motley Fool owns shares of and recommends Tesla. The Motley Fool has a disclosure policy.
CureVac NV (CVAC)
76.95 ? -8.73 (-10.19%)
Volume: 946,137 @11/17/20 1:16:45 PM EST
Bid Ask Day's Range
76.5 76.99 70.16 - 77.8
CVAC Detailed Quote
$CVAC Fauci says Covid-19 vaccine may not get US to herd immunity if too many people refuse to get it
https://www.cnn.com/2020/06/28/health/fauci-coronavirus-vaccine-contact-tracing-aspen/index.html
CureVac NV (CVAC)
50.11 ? 1.04 (2.12%)
Volume: 688,768 @10/23/20 7:51:12 PM EDT
Bid Ask Day's Range
40.0 67.0 49.5 - 52.89
CVAC Detailed Quote
mRNA is Trending as other Age Groups become COVID-19 Participants. Good for CureVac!
https://pennystocks.news/biontech-and-curevac-mrna-is-trending-as-other-age-groups-become-covid-19-participants-bntx/
... UH DUH $CVAC IS A BUY ...
On September 29, 2020, CureVac N.V. (the “Company”) issued a press release announcing that the Company has initiated a Phase 2a clinical trial of its COVID-19 vaccine candidate, CvnCoV. The dose-confirmation study, CV-NCOV-002, is being conducted in Peru and Panama and is expected to enroll a total of 690 healthy participants in two groups: older adults ages 61 and above, and younger participants 18 to 60 years old. The press release is attached hereto as Exhibit 99.1.
CureVac NV (CVAC)
44.2 ? -3.43 (-7.20%)
Volume: 619,533 @09/24/20 7:47:07 PM EDT
Bid Ask Day's Range
44.0 45.65 43.0 - 45.8
CVAC Detailed Quote
... hope this goes below $40 again shortly ... $CVAC
CureVac NV (CVAC)
62.9 ? 5.98 (10.51%)
Volume: 1,862,241 @09/04/20 7:59:28 PM EDT
Bid Ask Day's Range
62.5 63.28 57.05 - 64.18
CVAC Detailed Quote
CureVac Expected to Receive up to 252 million Euros from the German Federal Ministry of Research for Further COVID-19 Vaccine Development and Production Capacity Expansion
· Ministry submits official notification of funding to CureVac
· Grant as part of special program to accelerate COVID-19 vaccine development
TÜBINGEN, Germany / BOSTON, USA - September 4, 2020 - CureVac N.V. (Nasdaq: CVAC), a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) in clinical trials, has received notification from the German Federal Ministry of Education and Research (BMBF) that CureVac is expected receive up to 252 million euros to support the development of its COVID-19 vaccine candidate. In July 2020, CureVac had applied to a grant as part of a special program to accelerate the research and development of urgently needed vaccines against SARS-CoV-2. On July 29, the Federal Minister of Education and Research, Anja Karliczek, announced that CureVac and other companies were eligible for funding according to the recommendation of a panel of experts.
In addition to the further development of CureVac’s vaccine-candidate against COVID-19, the grant is expected to be used for the rapid expansion of the vaccine production. Payments are contingent on reaching predefined milestones. CureVac expects funding of up to 103 million euros in 2020 and up to 149 million euros in 2021.
Franz-Werner Haas, Chief Executive Officer of CureVac, said: "CureVac highly appreciates this significant and important financial support, which is expected to enable us to accelerate the development of our CVnCoV vaccine candidate as well as to increase our manufacturing capacity and, hence, to fight the COVID-19 pandemic. Given the significant costs related to the development of a safe and effective vaccine as well as to the extension of the manufacturing capacity, we believe that this grant can substantially support our efforts to produce and develop a safe and effective vaccine in high volume as quickly as possible."
"Musk announced in July that Tesla was building RNA microfactories "as a side project" for CureVac BV (NASDAQ: CVAC), which could potentially help manufacture the latter's COVID-19 vaccine — currently under development."
... looking for a significant drop to buy in again ... $CVAC
... CNBC COVERS TESLA CEO AT CUREVAC ...
In Germany.
... ELON GIVES THE $CVAC NEWS ...
BERLIN (Reuters) - Silicon Valley entrepreneur Elon Musk and German Economy Minister Peter Altmaier consider vaccine company CureVac (O:CVAC) as one the world's most innovative firms, a source said on Thursday, after Musk and Altmaier met on Wednesday.
Musk, who is CEO of Tesla (O:TSLA), during the meeting also discussed Tesla's investments in Germany as well as space technology and autonomous driving, the source familiar with the discussions told Reuters.
... CUREVAC AND TESLA PATENT REVEALED ... $CVAC
Curevac is going places.
- source
... BEFORE IT'S NEWS: TESLA AND CUREVAC ... #BREAKINGNEWS
BERLIN (Reuters) - Tesla Inc(TSLA) CEO Elon Musk is scheduled to meet German Economy Minister Peter Altmaier on Wednesday during a visit to Germany, coalition sources told Reuters.
... ANOTHER 1 - $CVAC TO $100 ... #BREAKINGNEWS
BRUSSELS, Aug 27 (Reuters) - The European Commission has made a 336 million euros ($396 million) downpayment to British drug maker AstraZeneca(AZN) to secure at least 300 million doses of its potential COVID-19 vaccine, a spokesman said on Thursday.
The deal covers development, liability and other costs faced by the vaccine maker. The EU has also secured an option to buy 100 million additional doses of the vaccine under development.
The 27 EU states could buy it at a later stage, should the vaccine prove successful.
The overall price they will pay to acquire the doses has not been revealed, but under an earlier deal struck in June with AstraZeneca(AZN) by Germany, France, Italy and the Netherlands, all members of the EU, AstraZeneca(AZN) agreed to sell 300 million doses for 750 million euros ($843 million).
The EU deal completed the preliminary accord reached with the drug maker by the four countries, the Commission said in a statement.
"We cannot indicate at this stage the specific pricing per dose. However, a significant part of the overall costs are funded by a contribution from the overall ESI funding for vaccines," the commission spokesman said, referring to the 336 million euros paid through the bloc's so-called emergency support instrument.
It is the first contract signed by the EU with a maker of potential COVID-19 vaccines. Brussels was previously said to be in advanced talks with Johnson & Johnson(JNJ), Sanofi , Moderna(MRNA) and CureVac(CVAC) for their potential vaccines.
EU officials told Reuters in July the bloc was also talking with Pfizer and BionTech for the shot they are developing together.
The contract with AstraZeneca(AZN) follows an advance purchase agreement signed by Brussels with the company earlier in August .
Part of the money the EU pays for supply deals covers legal risks faced by vaccine makers if their shots have unexpected side effects. These risks are increased by the hastened process to develop a vaccine in the race against the COVID-19 pandemic.
"In order to compensate for such high risks taken by manufacturers, the Advanced Purchase Agreements provide for member states to indemnify the manufacturer for liabilities incurred under certain conditions," the commission said.
"Liability still remains with the companies," it added.
This issue has been one of the stumbling blocs in talks with other vaccine makers, official told Reuters, as companies prefer to have a broader shield.
($1 = 0.8479 euros) (Reporting by Francesco Guarascio Additional reporting by Josephine Mason Editing by Jan Harvey and David Holmes)
$CVAC | #Curevac Potential Continuation Targets
Stock gapped up today as a result of a sizeable contract from the EU.
Technically the stock found support on the Fibonacci Golden Pocket (.65-.618).
Was somewhat surprising that there was no follow through in the afternoon session,
but lets see will tomorrow bring more gains.
7&12 moving averages support and holding above the VWAP
PLEASE GIVE US A LIKE IF YOU FIND OUR CONTENT HELPFUL, THANK YOU.
... definately a quiet buying opportunity again ... $CVAC #TheTrustedVaccine
$CVAC Meanwhile, in a call with reporters Thursday morning, a Food and Drug Administration official said that the agency’s external vaccine- advisory panel might meet on Oct. 22 to discuss a Covid-19 vaccine, according to Bloomberg. The official did not say which vaccine the panel would discuss, but Pfizer has said it hopes to have Phase 3 data on its vaccine by then.
The external advisory committee would likely need to weigh in before the FDA would issue an emergency-use authorization. And an Oct. 22 meeting would leave time for a vaccine to be approved before the election. Investors increasingly expect approval by then, despite worries from former FDA officials that the timing could undermine trust in the product.
All that comes after CureVac (CVAC) said early Thursday that it was in talks with the European Commission to sell it 225 million doses of its experimental Covid-19 vaccine, sending shares of the newly public stock up 14.7%.
* * $CVAC Video Chart 08-20-2020 * *
Link to Video - click here to watch the technical chart video
I like it! Keep goin!
Followers
|
9
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
175
|
Created
|
08/14/20
|
Type
|
Free
|
Moderators |
PARTNER
PARTNER
PARTNER
Respirational syncytial virus
PARTNER
DETAILS ON OTHER INFECTIOUS DISEASES
Rota, malaria, universal influenza
PARTNER
DETAILS ON VARIOUS PROJECTS
always like to check for a history of revenue growth. You can too, by accessing this free chart of historic revenue and earnings in this detailed graph.
If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future.
https://finviz.com/quote.ashx?t=cvac&ty=c&ta=1&p=d
Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments.
There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future.
The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least.
Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.
Insider ownership is positive when it signals leadership are thinking like the true owners of the company.
However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.
We can see that insiders own shares in CureVac N.V.. It is a very large company, and board members collectively own US$1.1b worth of shares (at current prices).
It is good to see this level of investment. You can check here to see if those insiders have been buying recently.
With a 21% ownership, the general public have some degree of sway over CureVac. While this group can't necessarily call the shots,
it can certainly have a real influence on how the company is run.
CureVac has entered into a collaboration with Arcturus Therapeutics Ltd. (NASDAQ:ARCT), an RNA medicines company,
to access the full suite of Arcturus’ lipid-mediated delivery intellectual property to enable the development of mRNA product candidates.
TÜBINGEN, Germany/ BOSTON, USA – August 14, 2020 – CureVac B.V. (“CureVac” or the “Company”), a clinical-stage biopharmaceutical company
developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), announced today the pricing of its
initial public offering of 13,333,333 common shares at an initial public offering price of $16.00 per common share, for total gross proceeds of approximately $213.3 million.
In addition, the Company has granted the underwriters a 30-day option to purchase up to an
additional 1,999,999 common shares at the public offering price, less underwriting discounts and commissions. All of the common shares are being offered by CureVac.
The shares are scheduled to begin trading on the Nasdaq Global Market today, August 14, 2020, under the ticker symbol “CVAC.”
The offering is expected to close on August 18, 2020, subject to customary closing conditions.
BofA Securities, Jefferies and Credit Suisse are acting as joint book-running managers for the proposed offering, with Berenberg and Kempen & Co acting as passive book-running managers.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission (“SEC”) on August 13, 2020.
The offering is being made only by means of a prospectus. Copies of the final prospectus relating to the offering may be obtained, when available,
for free by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, copies of the final prospectus, when available, may be obtained from
BofA Securities, Attention: Prospectus Department, NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, NC 28255-0001,
by telephone at (800) 299-1322 or by email at dg.prospectus_requests@bofa.com; Jefferies LLC, Attention:
Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at (877) 821-7388 or by email at Prospectus_Department@Jefferies.com;
and Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, 6933 Louis Stephens Drive, Morrisville, North Carolina 27560, by telephone at (800) 221-1037 or by email at usa.prospectus@credit-suisse.com.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities,
nor shall there be any sale of these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About CureVac
CureVac is a global clinical-stage biopharmaceutical company in the field of messenger RNA (mRNA) technology with expertise in developing
and optimizing this versatile molecule for medical purposes.
The principle of CureVac's proprietary technology is the use of mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases.
The company applies its technologies for the development of prophylactic vaccines, cancer therapies,
antibody therapies and the treatment of protein therapies. CureVac is headquartered in Tübingen, Germany with sites in Frankfurt and Boston, USA.
CureVac Investor Relation Contact
Dr. Sarah Fakih, Vice President Investor Relations
CureVac, Tübingen, Germany
T: +49 7071 9883-1298
M: +49 160 90 496949
sarah.fakih@curevac.com
CureVac Media Contact
Thorsten Schüller, Director Corporate Communications
CureVac, Tübingen, Germany
T: +49 7071 9883-1577
thorsten.schueller@curevac.com
sarah.fakih@curevac.com
*DISCLAIMER *The Board Monitor and The Board Assistants herewith, are not licensed brokers and assume NO responsibility for the actions, investment decisions, and or messages posted on this forum.
• We do NOT recommend that anyone buy or sell any securities posted herewith. Any trade entered into risks the possibility of losing the funds invested.
• There are no guarantees when buying or selling any security.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |